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Abstract
Purpose Combining molecular therapies with chemother-
apy may offer an improved clinical outcome for
chemoresistant tumours. Sphingosine-1-phosphate (S1P)
receptor antagonist and sphingosine kinase 1 (SK1) inhi-
bitor FTY720 (FTY) has promising anticancer properties,
however, it causes systemic lymphopenia which impairs its
use in cancer patients. In this study, we developed a
nanoparticle (NP) combining docetaxel (DTX) and FTY
for enhanced anticancer effect, targeted tumour delivery
and reduced systemic toxicity.
Methods Docetaxel, FTY and glucosamine were cova-
lently conjugated to poly(lactic-co-glycolic acid) (PLGA).
NPs were characterised by dynamic light scattering and
electron microscopy. The cellular uptake, cytotoxicity and
in vivo antitumor efficacy of CNPs were evaluated.
Results We show for the first time that in triple negative
breast cancer cells FTY provides chemosensitisation to
DTX, allowing a four-fold reduction in the effective dose.
We have encapsulated both drugs in PLGA complex NPs
(CNPs), with narrow size distribution of * 100 nm and
excellent cancer cell uptake providing sequential, sustained
release of FTY and DTX. In triple negative breast cancer
cells and mouse breast cancer models, CNPs had similar
efficacy to systemic free therapies, but allowed an effective
drug dose reduction. Application of CNPs has significantly
reversed chemotherapy side effects such as weight loss,
liver toxicity and, most notably, lymphopenia.
Conclusions We show for the first time the DTX
chemosensitising effects of FTY in triple negative breast
cancer. We further demonstrate that encapsulation of free
drugs in CNPs can improve targeting, provide low off-
target toxicity and most importantly reduce FTY-induced
lymphopenia, offering potential therapeutic use of FTY in
clinical cancer treatment.
Keywords FTY720  Docetaxel  Sensitisation  PLGA
nanoparticle  Breast cancer  Reduced toxicity 
Lymphopenia
Abbreviations
ALT Alanine aminotransferase
CNPs Docetaxel and FTY720 combination PLGA
nanoparticles
DCC Dicyclo carbodiimide
DCM Dichloromethane
DIPEA Diisopropylethylamine
DLS Dynamic light scattering
DMAP Dimethyl amino pyridine
DMF Dimethyl formamide
DMEM Dulbecco’s modified Eagle medium
Heba Alshaker, Qi Wang and Shyam Srivats have contributed equally
to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s10549-017-4380-8) contains supplementary
material, which is available to authorised users.
& Dmitri Pchejetski
d.pshezhetskiy@uea.ac.uk
1 School of Medicine, University of East Anglia, 2.53 BCRE,
Norwich Research Park, Norwich NR47UQ, UK
2 Department of Pharmacology and Biomedical Sciences,
Faculty of Pharmacy and Medical Sciences, University of
Petra, Amman, Jordan
3 University of California San Francisco, Health Sciences East
1350, San Francisco, CA 94143-0130, USA
4 School of Chemistry, University of East Anglia, Norwich,
UK
123
Breast Cancer Res Treat
DOI 10.1007/s10549-017-4380-8
DTX Docetaxel
FACS Fluorescence-activated cell sorting
FCS Foetal calf serum
FTY FTY720
Hb Haemoglobin
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SEM Scanning electron microscopy
SK1 Sphingosine kinase 1
t-Boc Di-tert-butyl dicarbonate
TEM Transmission electron microscopy
TFA Trifluoroacetic acid
VEGF Vascular endothelial growth factor
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Introduction
In the Western world, breast cancer is now the most
commonly diagnosed non-cutaneous cancer in women and
is the second leading cause of cancer-related deaths [1].
Docetaxel (DTX) is one of the most frequently used
chemotherapies for metastatic triple negative breast cancer,
however, it has serious adverse effects and many patients
relapse on treatment [2]. Thus, any improvement in
response to DTX chemotherapy would be of clear benefit.
Sphingosine kinase 1 (SK1) is a proto-oncogenic enzyme
that is highly expressed in human tumours and has been
shown to act as a ‘‘cancer signalling hub’’. SK1 mediates
cancer progression, angiogenesis and cell migration, mak-
ing it a key molecule in the search for potential anticancer
therapies [3]. High levels of SK1 expression were shown in
human breast tumours [4–6]. Targeting SK1 in human
cancer has therapeutic potential, and improves treatment
outcome [3, 7]. FTY720 (FTY) is a sphingosine analogue
and a sphingosine-1-phosphate (S1P) receptor antagonist
[8]. Pre-clinical studies showed the potential of FTY to
downregulate the expression and activity of SK1 and sen-
sitise cancer cells to conventional treatments such as
radiotherapy [9], sunitinib [10] and cetuximab [11]. Both
downregulation of S1P receptors and SK1 inhibition by
FTY lead to downregulation of phosphoinositol-3 kinase-
AKT and mitogen activated protein kinase pathways,
reduction in cyclin dependent kinases 2/4 and induction of
p21 [12, 13]. FTY is currently used for the treatment of
multiple sclerosis [14, 15] through induction of immune
suppression and lymphopenia, which impairs its use in
cancer patients.
Nanoparticle (NP)-based drug delivery systems offer
tumour-directed targeting, improved toxicity profiles and
capability of co-delivery of drug combinations. NP tumour
targeting is based on enhanced permeability and retention
effect, whereas tumour vasculature has leaky neo-angio-
genic vessels and impaired lymphatic drainage, which
allows NP entry and retention within the tumour
microenvironment [16]. Additionally, cancer specific pep-
tides or glucosamine [17] linked to NP surface may allow
targeting preferentially to the tumour microenvironment
[18]. Among different NP based drug vehicles, polymeric
NPs have been widely used due to their favourable
biodegradability, low antigenicity, and approval for drug
use [19]. To date, different strategies have been introduced
for preparing polymeric NPs such as physical loading [20]
and chemical conjugation [21, 22].
In this study, we have shown for the first time the
therapeutic benefit of combining FTY and DTX treatment
in triple negative breast cancer. To improve tumour tar-
geting and minimise toxicity, we have designed a combi-
national NP system where both DTX and FTY were
chemically conjugated to poly(lactic-co-glycolic acid)
(PLGA). To further improve the efficacy of our nanofor-
mulation, an active cancer targeting ligand, glucosamine
[23] was conjugated to PLGA. Using ester and amide
covalent bonds provided a sequential delivery of FTY and
DTX at the tumour site, increasing their efficacy. In mouse
tumours, NP encapsulation reduced systemic toxicity and
overcame FTY-induced lymphopenia.
Materials and methods
Materials
FTY720 and DTX were purchased from Selleck Chemicals
(Houston, USA) and LC laboratories (Woburn, USA),
respectively. Caspase-GLO kit was obtained from Promega
(Fitchburg, USA). Other reagents and chemicals used were
purchased from Sigma-Aldrich (Dorset, UK) unless
otherwise specified.
Synthesis and characterisation of NPs
Detailed NP synthesis method is provided in the supple-
mentary information. Briefly, to conjugate DTX or FTY
onto the PLGA polymer, two types of reactions were used.
First, the amine group of FTY was protected with di-tert-
butyl dicarbonate (t-Boc). It was then conjugated onto the
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PLGA backbone by steglich esterification. Second, DTX
was treated with a solution of 33% trifluoroacetic acid
(TFA) to retrieve the amine group. It was then reacted with
the carboxyl group of PLGA to form an amide bond.
Similar reaction was performed for conjugation of glu-
cosamine onto PLGA. The loading of each drug was
quantified by UV spectroscopy. Finally, the DTX-FTY
combination PLGA NPs (CNPs) were formulated using an
emulsion-solvent evaporation technique with the obtained
PLGA-FTY, PLGA-DTX and PLGA-glucosamine. The
respective doses of DTX and FTY were 5 nM and 2.5 lM.
The size and morphology of CNPs were investigated using
scanning electron microscopy (SEM) (JEOL SEM JSM
804A, UK), transmission electron microscope (TEM)
(JEOL 2011, UK) and Zetasizer Nano ZS90 (Malvern
Instruments, Malvern, UK). The in vitro stability of CNPs
was studied by dynamic light scattering (DLS) in five
different media: phosphate buffered saline (PBS), Dul-
becco’s modified Eagle’s medium (DMEM), DMEM plus
10% heat-inactivated foetal calf serum (FCS) (FirstLink,
Birmingham, UK), FCS and 10% human plasma. The
Release profile of CNPs was studied in pH 5 PBS using
UV–Vis spectrophotometer (Perkin Elmer, UK).
Cell culture
Human breast cancer cell line MDA-MB-231 and murine
breast cancer cell line 4T1 were purchased from ATCC
(Manassas, VA, USA), and maintained in DMEM with
10% FCS, 50 U/mL penicillin, 50 lg/mL streptomycin and
2 mM glutamine (Sigma-Aldrich, St. Louis, MO). Cell
lines were kept in culture for up to 30 passages. Cells were
seeded to reach 70–80% confluence by the end of the
treatment.
MTT viability assay
Both MDA-MB-231 and 4T1 cells were seeded in 96-well
plates and incubated for 24 h. After 24 h starvation, cells
were exposed to DTX, FTY, DTX ? FTY, empty CNP or
CNPs for 48 and 72 h. MTT assay was conducted as pre-
viously described [24, 25].
Caspases activation assay
4T1 and MDA-MB-231 breast cancer cells were cultured in
96 well plates and treated with free individual drugs, their
combination, empty CNP or CNPs. After incubation per-
iod, 100 lL of caspase3/7-GLO substrate was added and
incubated at 37 C for 1.5 h in the dark. Luminescence was
measured thereafter using Pherstart FS (BMG Tech, USA)
luminescence reader as described in [24, 25].
Fluorescent imaging and internalisation of CNPs
To obtain the fluorescent images of CNPs internalisation in
breast cancer cells, 4T1 cells were plated on glass cover-
slips coated with poly-L-lysine. After 24 h, rhodamine
tagged NPs were added, followed by lysotracker blue (Life
Technologies, UK). Cells were washed with PBS, fixed
using 4% paraformaldehyde, mounted onto glass coverslips
and imaged using Carl Zeiss confocal microscope. Fluo-
rescence-activated cell sorting (FACS) was also used to
confirm and quantify the uptake of CNPs in 4T1 and MDA-
MB-231 cells. Cells were incubated with rhodamine tagged
CNPs, and collected at each designated time point. They
were then stained with 5 lL of Annexin FITC (BD bio-
sciences, UK) and 5 lg/mL aqueous solution of propidium
iodide (BD biosciences, UK). The fluorescence signal was
measured by FACS (Becton, Dickinson and Company,
Erembodegem, Belgium), which gating was constructed
based on stained and unstained positive and negative
controls.
Sphingosine kinase 1 (SK1) assay
SK1 assay was performed using radiolabelling as described
previously [5, 25, 26], in conditions favouring SK1 activity
and inhibiting SK2 activity. Briefly, cell lysates were
resuspended in SK1 buffer (20 mM Tris–HCl pH7.4, 20%
glycerol, 1 mM 2-mercaptoethanol, 1 mM EDTA, 10 lg/
mL Phenylmethanesulfonyl fluoride, 15 mM NaF, 10 lg/
mL leupeptin, aprotinine, soybean trypsin inhibitor,
0.5 mM 4-deoxypyridoxine, 40 mM B-glycerophosphate,
1 mM Sodium orthovanadate). Lysates were sonicated and
centrifuged at 20,000 g for 30 min at 4 C. 50 mM sph-
ingosine, 20 mM MgCl2, 20 mM ATP and 10 lCi [c-
32P]-
ATP (6000 Ci/mmol) were added and samples were incu-
bated for 1 h at 37 C. The reaction was stopped by
addition of 1 M HCl, chloroform/methanol/HCl, and 2 M
KCL. After centrifugation, the lower organic phase was
collected and vaporised. Dried lipids were solubilised with
chloroform/methanol (2:1, v/v) and separated by thin layer
chromatography on silica gel G60 plates using 1-butanol/
ethanol/acetic acid/water (80:20:10:20, v/v) as migration
solution. Plates were air-dried, exposed to X-ray film and
quantified using Image J software.
Quantitative real time-PCR (qRT-PCR)
qRT-PCR was performed as described previously [5, 26]
using PrecisionTM 2X qPCR Mastermix with SYBR green
(PrimerDesign Ltd, Southampton, UK). Ct values were
exported and analysed using qbase software (Biogazelle
NV, Zwijnaarde, Belgium).
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Animal studies
Breast cancer allografts were established in 6–8 week
BALB/c nude mice (Charles River Ltd, UK) by injection of
1 9 106 4T1 cells into their mammary pad. Two weeks after
implantation, mice were randomised into treatment groups
(n = 6/group) and treated twice a week for two weeks with:
intravenous tail vein injections of: saline, 5 mg/kg DTX,
3 mg/kg FTY, 5 mg/kg DTX ? 3 mg/kg FTY, empty
CNPs, CNP1 (5 mg/kg DTX ? 3 mg/kg FTY), CNP2
(2 mg/kg DTX ? 2 mg/kg FTY). One day after the last
treatment, all mice were euthanised and blood was collected.
Full blood counts and blood biochemistry were performed
by National Veterinary Services Ltd in a blinded manner.
Biochemical analysis was performed using a Werfen IL650
photometric clinical chemistry system. Haematological
analysis was performed using flow cytometry (Siemens
Advia 120). Mice, tumours and individual organs were
weighed. 5 9 5 9 5 mm blocks of tumours and individual
organs were paraffin fixed and stereomicroscopy was per-
formed using Widefield Zeiss SV11 stereo microscope with
emission measured at 530 nm. The levels of fluorescence in
each organ were quantified using ImageJ. Animal studies
were performed under the Home Office licence and carried
out in accordance with the institutional guidelines and reg-
ulations for animal welfare and NC3Rs (Replacement,
Reduction and Refinement) guidelines.
Statistical analysis
The statistical significance of differences between the
means of two groups was evaluated by unpaired two-sided
student’s t test. Calculations were performed using
GraphPad Prism software. p value of\0.05 is considered
statistically significant.
Results
Synthesis of CNPs
CNPs were synthesised using emulsion-solvent evaporation
technique using DTX- and FTY-conjugated PLGA (Fig. 1).
The amine group along with the octyl tail of FTY enables its
recognition as a sphingolipid to inhibit the activity of SK1
(Fig. S1) [27]. Therefore, to design the ester linked PLGA-
FTY conjugate, it was essential to protect its amine group
using an acid labile moiety as the lysosomal cavity is acidic
with a pH 5 [28]. The amine of FTY was protected using
t-Boc, an ester anhydride in a basic environment using
diisopropylethylamine (DIPEA) (Fig. 1a), which was con-
firmed using nuclear magnetic resonance (NMR) (Fig. S2).
It was then reacted with PLGA wherein the carboxylic acid
of the polymer was activated using dicyclo carbodiimide
(DCC) and to catalyse ester linkage formation, dimethyl
amino pyridine (DMAP) was added (Fig. 1a). In the case of
DTX, the functional amine group is protected by t-Boc
naturally. Deprotection was carried at 50% TFA in
dichloromethane (DCM) (Fig. 1a) to revive the functional
group and preserve the anti-mitotic activity of the drug.
The loading of FTY and DTX (assessed using UV–Vis
spectrometer) was 60.2 ± 4.5 lg/mg and 30.6 ± 12.5 lg/
mg of polymer, respectively. Glucosamine was conjugated
to PLGA by an amide bond as shown in Fig. 1a by loading
72.3 ± 2.1 lg per mg of polymer.
The drug ratio in CNPs was designed based on the cell
viability testing (Fig. S3), where a combination of 5 nM
DTX and 2.5 lM FTY showed potentiating effect in
comparison to DTX or FTY alone. Factoring the percent-
age yield of PLGA-FTY, PLGA-DTX and PLGA-glu-
cosamine conjugates, we designed the combination ratio as
20:0.1:2 (weight %), respectively (Fig. 1b).
Characterisation of CNPs
CNPs were characterised by SEM, TEM and DLS as
shown in Fig. 2a–c. The CNPs were sphere shaped with the
size of 91.51 ± 1.37 nm and a very small polydispersity
index (PDI) of 0.05 ± 0.005. These parameters were
retained during 14 days. The CNPs were negatively
charged with zeta potential of -14.0 ± 0.6 mV.
Sustained release profile is an essential characteristic of
NPs as this facilitates reduced drug intake in patients and
effective therapy at the diseased site [29]. The release
profile of DTX and FTY, was quantified over 120 h in pH 5
acidified PBS (replicating lysosomal environment)
(Fig. 2d). Our data show sustained, sequential release of
both FTY and DTX from CNPs, with *52% of FTY
and *25% of DTX released after 24 h (Fig. 2d).
A significant challenge in the application of NPs is to
retain their stability in application-associated environ-
ments. Aiming at biomedical applications, we evaluated
the colloidal stability of CNPs by dissolving them in five
different biological media: PBS, DMEM, DMEM with
10% of FCS, pure FCS, and 10% (v/v) human plasma
solution (diluted in PBS). The particle characteristics (size
and PDI) were measured by DLS over a period of 5 days to
monitor if any aggregation would occur. As shown in
Fig. 2e, there was no significant change in NP size during
the observation period for CNPs suspended in PBS or
culture media, suggesting the NPs could be stored for long
periods of time with little or no aggregation.
In the presence of serum or human plasma there was no
significant change in NP size (Fig. 2e), however there was
a significant increase in PDI (Fig. 2f), that was maintained
throughout the 5 days of study.
Breast Cancer Res Treat
123
In vitro internalisation and cytotoxicity effects
of CNPs
4T1 cells were incubated with CNPs labelled with rho-
damine 123 for 8 h and then counter stained with lyso-
tracker blue. Fluorescent microscopy revealed
internalisation of CNPs into the endolysosomal compart-
ments (Fig. 3a). Flow cytometry showed a time-dependent
internalisation of CNPs during 36 h, demonstrating a rapid
accumulation of the CNPs within the cells (Fig. 3b).
Following internalisation, in 4T1 cells, CNPs containing
5 nM DTX and 2.5 lM FTY have significantly reduced
Fig. 1 Synthesis of CNPs. a Schematic representation of drug
modifications: amine head protection in FTY720 (FTY, blue stars)
to facilitate ester conjugation with PLGA. Deprotection of amine
group in docetaxel (DTX, red triangles) and amide conjugation with
PLGA. Amide conjugation reaction between glucosamine (black
coils) and PLGA. b Synthesis of CNPs through self-assembly from
PLGA-FTY, PLGA-DTX and PLGA-glucosamine. DCC dicyclo
carbodiimide, DCM dichloromethane, DIPEA diisopropylethylamine,
DMAP dimethyl amino pyridine, DMF dimethyl formamide, HBTU
N,N,N0,N0-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluo-
rophosphate, t-Boc di-tert-butyl dicarbonate, TFA trifluoroacetic acid,
PVA poly vinyl alcohol
Breast Cancer Res Treat
123
intracellular SK1 activity. Their effect was inferior to free
drugs at 24 h (37 vs. 47% inhibition), but superior at 48 h
(56 vs. 42% inhibition) (Fig. 3c). Similar to free drugs,
CNPs also reduced SK1 mRNA expression (Fig. 3d). CNPs
also had similar effects on expression of vascular
endothelial growth factor (VEGF), which was chosen as a
surrogate marker of tumour angiogenesis (Fig. 3e). Of
note, downregulation of SK1 and VEGF were present in
cells treated with FTY alone, while DTX on its own
increased SK1 and VEGF mRNA. Similar results were
obtained in MDA-MB-231 cells (Figs. S4, S5).
In this study, we demonstrate for the first time that in both
triple negative human MDA-MB-231 and mouse 4T1 cell
lines free FTY has potentiated the chemotherapy effect of
DTX (Figs. 4, S3). This is likely to be achieved through
downregulation of SK1 expression and activity (Figs. 3, S3).
Fig. 2 Characterization of
CNPs. Morphology of CNPs
was assessed by SEM (a) and
TEM (b). Scale bars indicate
1 lm and 100 nm, respectively.
c Distribution of hydrodynamic
diameter of PLGA NPs in PBS
solution stored for 14 days at
4 C measured using DLS.
d Physiochemical release of
DTX and FTY was quantified
over 120 h using UV–Vis
spectrophotometer. e, f CNPs
were incubated in solutions
shown on graphs for 5 days.
CNP size (e) and polydispersity
index (PDI) (f) were measured
as described in methods. Points,
mean of three independent
experiments performed in
triplicate. Data is presented as
mean ± SE. ns non-significant,
*p\ 0.05, **p\ 0.01,
§p\ 0.001 (in d vs. DTX; in e,
f vs. PBS)
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Similarly to combined free drugs, CNPs containingDTXand
FTY have induced significant loss of viability in MDA-MB-
231 and 4T1 breast cancer cells (Fig. 4a, b). To study the
effect of CNPs on apoptosis induction, caspases 3/7 activity
assay was performed. As shown in Fig. 4c, d, both CNPs and
free drugs have induced a rapid increase in caspases 3/7
enzymatic activity, which was superior to individual drugs.
CNPs had a lag in comparison to free drugs combination,
however, showed comparable efficacy at 48-72 h.
Accumulation of CNPs at tumour sites and their
antitumor effect in vivo
To investigate the in vivoefficacy ofCNPs,we inoculated4T1
cells into the mammary pad of 6–8 week-old female BALB/c
nude mice. Tumour-bearing mice were sorted into groups
(n = 6) and injected with 5 mg/kg DTX, 3 mg/kg FTY,
5 mg/kgDTX ? 3 mg/kgFTY, emptyCNP,CNP1 (5 mg/kg
DTX ? 3 mg/kg FTY), CNP2 (2 mg/kg DTX ? 2 mg/kg
FTY). Two weeks after the inoculation, mice were treated
twice a week with intravenous injection of the drugs for two
weeks. In the control (saline and the empty CNP) groups,
tumours grew progressively and rapidly reaching 478 and
407 mm3, respectively (Fig. 5a). Individual FTY did not
significantly affect tumour growthwith amean tumour size of
438 mm3, while mice in DTX group had tumours of
269 mm3. Conversely, the combined free therapy group had a
significantly lower mean tumour volume of 135 mm3. CNP1
andCNP2 had a similar efficacy in slowing the tumour growth
and keeping the tumour volume at *200 mm3 (Fig. 5a). In
all treatment groups containing FTY, SK1 activity
was *40% lower than in control group and *30% lower
than in DTX group (Fig. 5b). All treatment groups containing
FTY reducedSK1 andVEGF expression by *40% (Fig. 5c).
Fig. 3 CNPs internalise into
cancer cells and reduce SK1
activity and expression.
a Representative fluorescent
microscopy images showing
internalisation of CNPs in 4T1
cells. Images were captured at
63X using a Carl Zeiss confocal
microscope after 8 h of
incubation with rhodamine
labelled CNPs. Cells were
counter stained with lysotracker
blue. Colocalization signals
from superimposed images
reveal internalisation of CNPs
into the endolysosomal
compartments. b Fluorescence-
activated cell sorting (FACS)
assisted quantification of
rhodamine labelled CNPs
internalisation over 36 h time
period in MDA-MB-231 and
4T1 cells. c–e 4T1 cells were
treated with DTX-FTY free
drug combination
(5 nM ? 2.5 lM, respectively)
or CNPs (containing same doses
of DTX and FTY) for 24 h and
48 h. c SK1 activity was
measured using radiolabeling.
Expression of SK1 (d) and
VEGF (e) was determined by
qRT-PCR and analysed using
qBase software. Graphs show
mean of three independent
experiments performed in
triplicates. Data is presented as
mean ± SE. ns non-significant,
*p\ 0.05, **p\ 0.01,
§p\ 0.001 vs. control
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To investigate CNPs tumour targeting, rhodamine123
labelled CNPs were injected in the last treatment cycle.
Fluorescence imaging of mice organs and primary tumour
were obtained using a stereo microscope. As shown in
Fig. 5d, the fluorescent signal in tumour was at least four-
fold higher than the signal in other organs.
Chemotherapy-induced whole body toxicity is a key
limiting factor for the administration of effective
chemotherapy doses in cancer patients. In mice, systemic
free DTX or combined drug therapy, induced a 20%
reduction in total body weight (Fig. 6a), insignificantly
decreased liver weight (Fig. 6b) and significantly reduced
spleen weight (Fig. 6c). Furthermore, free treatments sig-
nificantly increased liver alanine aminotransferase (ALT)
levels and reduced white cell count (WCC), red blood cell
count (RBC) and haemoglobin (Hb) (Fig. 6d–g). In con-
trast, CNPs have markedly reversed all these surrogate
markers of overall toxicity and morbidity (Fig. 6).
Discussion
Enveloping drugs into nanocarriers offers significant
advantages including tumour targeting, enhanced delivery
and efficacy together with low systemic toxicity. Recent
evidence show that nanoformulations provide significant
advantage to breast cancer molecular therapies and
chemotherapies allowing significant improvement in drug
delivery and imaging [30–32]. This is particularly true for
docetaxel and paclitaxel [33] where nanoformulations
outperform systemic therapies [34, 35]. Abraxane, a
130 nM simple albumin NP-bound paclitaxel that is cur-
rently licenced for use in breast, lung and pancreatic can-
cers. NP binding solubilises hydrophobic paclitaxel and
provides a higher maximum whole-blood concentration,
shorter time to peak concentration, larger distribution
volume and greater clearance than a conventional poly-
oxyethylated castor oil solubilised paclitaxel [36, 37]. A
hallmark phase III trial in women with metastatic breast
cancer showed that patients receiving abraxane had longer
time to tumour progression (23.0 vs. 16.9 weeks,
p = 0.006) and objective response rate (33 vs. 19%,
p = 0.001) than patients receiving conventional paclitaxel
[38]. A systematic review and meta-analysis of further
randomised clinical trials, showed that the probability of
achieving pathological complete response was significantly
higher in the abraxane group than in the conventional
taxanes group (odds ratio = 1.383, 95% CI 1.141–1.676,
p = 0.001) [39]. Abraxane was also administered to
patients with chemotherapy-naive advanced breast cancer,
Fig. 4 CNPs reduce cancer cell
viability and induce apoptosis
through caspases 3/7 activation.
4T1 and MDA-MB-231 breast
cancer cells were treated with
5 nM DTX ? 2.5 lM FTY or
CNPs with same doses of drugs
for 72 h. Cell viability of 4T1
(a) and MDA-MB-231 (b) cells
was measured using MTT assay.
Caspases 3/7 activity in 4T1
(c) and MDA-MB-231 (d) cells
was measured using caspases
3/7 luminescence assay. Graphs
depict quantification of three
independent experiments
performed in triplicates. Data is
presented as mean ± SE. ns
non-significant, *p\ 0.05,
**p\ 0.01, §p\ 0.001 vs
control
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however it was not superior to paclitaxel and had a trend
toward inferiority and higher toxicity [40].
Polymers are highly biocompatible and are commonly
used for the synthesis of drug-containing NPs [41]. Poly-
mer NPs show structural stability and are able to encap-
sulate drugs with high capacity [42]. PLGA is a well-
characterised biodegradable polymer widely used for drug
delivery and approved for clinical use by the US Food and
Drug Administration [29]. It has good toxicity profiles and
an enhanced ability to self-assemble into NPs.
We have designed our CNPs aiming for a controlled,
time-dependent and sustained drug release profile to
achieve maximum therapeutic efficacy [29]. To achieve
that DTX was conjugated to the PLGA backbone via an
amide bond (harder to degrade in acid environment) and
FTY by an ester bond (quicker to degrade) (Fig. 1), leading
to a speedier release of FTY (Fig. 2d).
Glucose is an important metabolite for all cells in a
living organism as it provides the energy required to carry
out all the essential cellular activities. In case of active
Fig. 5 CNPs inhibit 4T1
murine breast tumour growth
and SK1 expression and
activity. 106 4T1 breast cancer
were implanted subcutaneously
in 6–8 week-old female nude
mice. Tumours were grown for
2 weeks and then treated for 2
weeks biweekly with
intravenous: control (1%
dimethyl sulfoxide in saline),
empty CNP, 5 mg/kg DTX,
3 mg/kg FTY, free DTX-FTY
(5 mg/Kg DTX and 3 mg/Kg
FTY), CNP1 (containing 5 mg/
Kg DTX ? 3 mg/Kg FTY) and
CNP2 (containing 2 mg/Kg
DTX ? 2 mg/Kg FTY).
a Tumour volume. b Tumour
SK1 activity. c Tumour SK1
and VEGF expression.
d Fluorescent microscopy of
mouse organs and primary
tumours. Graph indicates the
levels of fluorescence in each
organ quantified using ImageJ.
Data is presented as
mean ± SE. ns non-significant,
*p\ 0.05, **p\ 0.01,
§p\ 0.001 vs. control group
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mitotic cells (such as cancer cells), the requirement of
glucose is five-fold higher compared with the normal
healthy cells [28]. Here we used glucosamine as a tumour
targeting ligand to improve the onsite delivery of CNPs. It
was conjugated to PLGA by an amide bond as shown in
Fig. 1a.
We aimed the CNPs size to be between 40 and 200 nm
to allow the best tumour targeting according to enhanced
permeability and retention theory [43]. SEM demonstrated
a clear spherical morphology of the CNPs (Fig. 2a), which
was shown to enhance their tumour incorporation com-
pared to rod- and disc-shaped NPs [44]. A detailed imaging
by TEM further confirmed SEM findings (Fig. 2b). DLS
showed a narrow monodisperse CNPs distribution at
91.51 ± 1.37 nm (Fig. 2c). Prolonged incubation of CNPs
in PBS showed excellent stability. The CNPs were
Fig. 6 In vivo CNPs demonstrate reduced toxicity in comparison
with systemic therapy. 4T1 breast tumours were grown in female
nude mice for 2 weeks and treated biweekly in the last two weeks
with control, empty CNP, DTX, FTY, free DTX-FTY, CNP1 and
CNP2 (as indicated in the legend of Fig. 5). a Mouse body weight.
b Liver weight. c Spleen weight. d Serum alanine aminotransferase
(ALT). e White cell count (WCC). f Red blood cell count (RBC).
g Haemoglobin (Hb). Data is normalised vs control group and
presented as mean ± SE, ns non-significant, *p\ 0.05, **p\ 0.01,
§p\ 0.001 vs. control group
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negatively charged with zeta potential of -14.0 ± 0.6 mV,
which in some cases may delay the CNPs cellular uptake
due to the negatively charged cell plasma membrane [45].
A significant challenge in the clinical use of NPs is to
retain their stability in body environments. The synthesised
CNPs had a good colloidal stability in five different bio-
logical media: PBS, DMEM, DMEM with 10% of FCS,
pure FCS, and 10% (v/v) human plasma solution (diluted in
PBS) (Fig. 2e, f). There was no significant change in size
and PDI during the observation period for CNPs suspended
in PBS or cell culture media, suggesting the NPs could be
stored for long periods of time with little or no aggregation.
In the presence of serum, an initial of 0.3 and 0.5 increase
of PDI was observed and remained unchanged throughout
the five days of observation, suggesting some degree of
aggregation (Fig. 2f), which however, did not significantly
affect average NP size (Fig. 2e). This can be avoided by
further modification of the NP surface with polyethylene
glycol [46].
Fluorescent microscopy showed a quick and sustained
CNPs cellular uptake (Fig. 3a, b). CNPs were colocalised
with lysotracker dye demonstrating their preferred
endolysosomal distribution. In 4T1 and MDA-MB-231
cells CNPs have successfully supressed SK1 activity
(Figs. 3c, S4). They were slightly less efficient than free
drugs at 24 h and a little more efficient at 48 h, most likely
due to delayed internalisation in comparison to free drugs
and longer half-life [47]. Of note, there was no statistical
difference between the CNPs and combined free drug
treatments. Similar to combined free drugs, CNPs reduced
mRNA expression of SK1 by *30 and *40% at 24 and
48 h, respectively (Fig. 3d) and to a lesser extent of VEGF
(Fig. 3e). All treatments containing FTY have induced a
similar downregulation of SK1 and VEGF, while DTX on
its own increased SK1 and VEGF mRNA (Figs. 3, S3).
These data support the use of FTY as a molecular sensitiser
to DTX as it increases the responsiveness of cancer cells to
chemotherapy. Similar results were obtained in MDA-MB-
231 cells (Fig. S5). Considering a concomitant decrease in
SK1 activity and expression, it is possible that the decrease
in SK1 activity is at least partially mediated through the
downregulation of its expression.
Here we show for the first time that in both 4T1 and
MDA-MB-231 triple negative breast cancer cell lines FTY
has potentiated the chemotherapy effect of DTX (Figs. 4,
S3) and allowed a four-fold reduction in effective DTX
dose (from 20 nM as studied previously to 5 nM)
[24, 48, 49]. This effect is likely achieved through the
downregulation of SK1 (Figs. 3, S3–S5), which we have
demonstrated to be a key element in cancer cell resistance
to DTX therapy [24, 48, 49]. The distinct conjugation of
FTY and DTX via ester and amide bonds, respectively,
resulted in speedier FTY release (52 at 24 h vs. 25% for
DTX) in pH 5 acidified PBS buffer (replicating lysosomal
environment) (Fig. 2d). We hypothesise that this earlier
release of FTY may enable lowering cellular defence
mechanisms [through downregulation of SK1 activity
(Fig. 3)] and allow chemosensitisation to DTX (Figs. S3,
4). Indeed, the effective uptake of CNPs by breast cancer
cells has led to a significant loss of cell viability at 48 h and
72 h (Fig. 4a, b). CNPs had comparable cytotoxicity to free
drugs, but took 24 h longer to achieve full efficacy, likely
due to longer time required for cell uptake and internal
degradation in comparison to free drugs. Caspases 3/7
activity assays confirmed that in both breast cancer cell
lines, CNPs induced apoptosis through activation of exe-
cutioner caspases (Fig. 4c, d). Free drugs were more effi-
cient in inducing caspases activation, but had similar levels
of cell viability reduction.
To investigate the in vivo efficacy of CNPs, we estab-
lished subcutaneous breast tumours in female nude mice
through inoculation of 4T1 cells into the mammary pad.
Tumour-bearing mice were treated biweekly with either
DTX, FTY, their combination or CNPs containing equal, or
smaller amounts of drugs. Our data clearly show that
DTX ? FTY is an effective chemotherapy combination for
the treatment of triple negative breast cancer tumours,
resulting in[3-fold reduction in tumour volume in com-
parison to control. Importantly, both CNPs (including the
ones with lower drug concentrations) had comparable
effects to free drugs (Fig. 5a). In all treatment groups
containing FTY, SK1 activity and expression was *40%
lower than in control (Fig. 5b, c). These results demon-
strate that nanoformulated DTX-FTY has similar antitumor
effects to FTY and DTX combination as free drugs. These
data point out a possibility of drug dose reduction without
losing chemotherapeutic efficacy through effective tumour
targeting.
To investigate CNPs targeting properties, rhodamine123
labelled CNPs were injected in the last treatment cycle.
Fluorescence signals of mice organs and primary tumour
were obtained using a stereo microscope. As shown in
Fig. 5d, the fluorescent signal in tumour was four-fold
higher than the signal in other organs, suggesting primary
tumour targeting and minimal penetration into other
tissues.
Chemotherapy-induced toxicity is a key limiting factor
for the administration of effective chemotherapy doses in
cancer patients. Here we clearly demonstrate that CNPs
had significant advantages over the free drugs in all mea-
sured parameters including: body weight, liver and spleen
size and ALT (Fig. 6). These data suggest that the severe
liver damage associated with free drug administration was
alleviated through nanoformulation.
The major obstacle for FTY use in cancer patients is
significant lymphopenia and anaemia induced by this drug
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due to T cell sequestration to lymph nodes [8]. Haemato-
logical assessment revealed that free FTY has significantly
reduced WCC after two weeks of administration (Fig. 6e).
In contrast, enveloping drugs in CNPs has improved WCC
and RBC by three- and two-fold, respectively, effectively
overcoming FTY-induced lymphopenia. Recent data show
that low doses of systemic FTY can rather promote tumour
growth through accumulation of myeloid-derived sup-
pressor cells, which suppressed antitumor immune
response [50]. This important evidence adds a crucial
argument towards using targeted FTY tumour delivery for
improved outcomes.
Here, we show for the first time that new self-assembled
PLGA CNPs containing covalently bound DTX and FTY
induce significant apoptosis in triple negative breast cancer
cell lines. In accordance with our previous findings in
prostate cancer, our data indicate that FTY sensitises can-
cer cells to DTX, via SK1 inhibition and the CNP platform
facilitates this by the sequential release of drugs through
conjugation of FTY via a more labile ester bond and DTX
via a more stable amide bond. The *100 nm size range of
CNPs and glucosamine presence enable their preferential
delivery at the tumour site due to leaky tumour vessels and
higher glucose metabolic rate, which is key to reducing
systemic side effects. Most importantly, our study provides
an evidence that CNPs encapsulation of FTY can reduce
systemic lymphopenia and anaemia [9, 51], making it a
candidate drug for use in cancer patients.
Overall, we show that using systemic protection, targeted
delivery and imaging capability provided by CNPs encap-
sulation, FTY/DTX combination may have a potential
therapeutic use in clinical cancer treatment and demonstrate
a platform basis for a SK1 inhibitor/chemotherapy combi-
nation in nanoformulation. Future work through peptide or
antibody mediated targeting may further enhance the tar-
geting properties and therapeutic outcome.
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